Evaluating contributions of neuropsychological, psychiatric, and inflammatory processes to the expression of cognitive symptoms in post-acute COVID-19 syndrome
Taken together, cognitive sequelae of PACS appear to be rooted in changes in brain function that are detectable by objective neuropsychological testing. Although comorbidities associated with PACS can contribute to the experience of cognitive symptoms, we find cognitive symptoms, whether self-reported or observed, to be more directly associated with neuropsychological test performance than ongoing fatigue, psychiatric symptoms, or inflammatory processes.
Authors
- Núria Guillén (ORCID: https://orcid.org/0000-0002-1341-9834)
- Youssef Toubouti
- Luke S. Watson (ORCID: https://orcid.org/0000-0002-2063-6925)
- Agnès Pérez-Millan
- Lorena Rami
- Jason K. Johannesen
- Sarah M. Gray
- Raquel Sanchez-Valle
Institutions
- Universitat Oberta de Catalunya (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Hospital Clínic de Barcelona (ES)
- Sage Therapeutics (United States) (US)
- Fundació Clínic per a la Recerca Biomèdica (ES)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fpsyt.2025.1668380
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sage Therapeutics
- Supernus Pharmaceuticals
- Generalitat de Catalunya